Search Result

Results for "

MAGL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MAGL (50) Autophagy (3) Bacterial (1) Biochemical Assay Reagents (1) Calcium Channel (1) Cannabinoid Receptor (2) DAGL (3) Drug Derivative (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (2) Environmental Pollutants (1) Exosomes (1) FAAH (14) Fungal (1) Histamine Receptor (1) Influenza Virus (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Lipase (1) NF-κB (1) Phospholipase (1) PROTACs (1) Reference Standards (2) SARS-CoV (1) Small Interfering RNA (siRNA) (3) VEGFR (1)
By Research Areas:	Cancer (13) Infection (2) Inflammation/Immunology (12) Metabolic Disease (8) Neurological Disease (37)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: MAGL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15249

JZL 184 Maximum Cited Publications 8 Publications Verification	MAGL	Neurological Disease
JZL 184 is a potent, selective and irreversible *MAGL* inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC₅₀ of 8 nM). JZL 184 displays >300-fold selectivity for *MAGL* over FAAH .

HY-119283

CAY10499 1 Publications Verification MAGL-IN-5	MAGL FAAH SARS-CoV Influenza Virus	Infection Metabolic Disease Inflammation/Immunology
CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC₅₀ values of 144 nM and 14 nM for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. Additionally, CAY10499 exhibits anti-inflammatory and antiviral activities .

HY-117632

Elcubragistat 2 Publications Verification ABX-1431	MAGL	Neurological Disease
Elcubragistat (ABX-1431) is a highly effective, selective, orally active, and blood-brain barrier-permeable monoacylglycerol lipase (MAGL) inhibitor, with an IC₅₀ value of 14 nM .

HY-117474

MJN110 5 Publications Verification	MAGL	Neurological Disease
MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC₅₀s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity .

HY-15250

JZL195 4 Publications Verification	FAAH MAGL Autophagy	Neurological Disease
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC₅₀s of 2 and 4 nM, respectively .

HY-117771

DO34 5 Publications Verification	DAGL	Neurological Disease Metabolic Disease
DO34 is a selective DAGL inhibitor, with an IC₅₀ of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 blocks de novo 2-AG synthesis, and suppresses tonic CB₁ receptor activation. DO34 blocks depolarization-induced suppression of excitation and inhibition in the cerebellum and hippocampus. DO34 regulates feeding behavior and locomotor activity in mice. DO34 abolishes AM251-mediated enhancement of parallel fiber-evoked excitatory postsynaptic currents in cerebellar slices from MAGL global knockout mice. DO34 can be used for the research of energy balance disorder and neuroinflammation .

HY-18977

KML29 3 Publications Verification	MAGL	Metabolic Disease Inflammation/Immunology
KML29 is an extremely selective, orally active and irreversible *MAGL* inhibitor, with IC₅₀ values of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively. KML29 exhibits minimal cross-reactivity toward other central and peripheral serine hydrolases, including no detectable activity against FAAH .

HY-108613

JJKK 048 2 Publications Verification	MAGL	Neurological Disease Cancer
JJKK 048 is a highly selective and potent monoacylglycerol lipase (MAGL) inhibitor with IC₅₀ values of 214 pM, 275 pM and 363 pM for human, rat, and mouse MAGL. JJKK 048 displays low cross-reactivity with other endocannabinoid targets. JJKK 048 can be used in the research of diseases such as cancer, neurodegenerative diseases, and pain .

HY-77491

*FAAH/MAGL-IN-5*	FAAH MAGL	Neurological Disease
AM6701 is a potent *FAAH/MAGL* inhibitor (equipotent inhibitory IC₅₀: 1.2 nM) with neuroprotective effects .

HY-N2512

1-Monomyristin 1 Publications Verification	Environmental Pollutants Endogenous Metabolite FAAH Autophagy Bacterial Fungal	Infection Cancer
1-Monomyristin acts as an insecticide, enzyme inhibitor, antibacterial and antifungal agent, with an IC₅₀ of 18 μM against rat FAAH and an IC₅₀ of 32 μM against rat *MAGL. 1-Monomyristin inhibits 2-oleoylglycerol hydrolysis via MAGL. 1-Monomyristin suppresses the growth of Staphylococcus aureus, Aggregatibacter actinomycetemcomitans* and Candida albicans. 1-Monomyristin is lethal to brine shrimp . 1-Monomyristin exhibits marginal cytotoxicity against prostate cancer cells. 1-Monomyristin is applicable to research related to bacterial infections, fungal infections, renal cancer, prostate adenocarcinoma and pancreatic cancer .

HY-12332

JW 642 3 Publications Verification	MAGL	Neurological Disease
JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.6, 14, and 3.7 nM for inhibition of MAGL in mouse, rat, and human brain membranes, respectively.

HY-132310

MAGL-IN-4	MAGL	Neurological Disease
MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .

HY-116141

7-Hydroxycoumarinyl arachidonate 7-HCA; Umbelliferyl Arachidonate; 7-HC-arachidonate	Phospholipase MAGL	Others
7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonate is also a fluorogenic substrate for monoacylglycerol lipase (MAGL). MAGL protein catalyzes the hydrolysis of 7-Hydroxycoumarinyl arachidonat to generate Arachidonic acid (AA) and the highly fluorescent 7-hydroxyl coumarin (7-HC; HY-N0573). Release of 7-HC can be measured using a fluorometer .

HY-133130

JNJ-42226314 1 Publications Verification	MAGL	Neurological Disease
JNJ-42226314, a chemical probe, is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .

HY-111538

MAGL-IN-1 1 Publications Verification	MAGL	Cancer
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of *MAGL, with an IC₅₀* of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .

HY-177093

Irafamdastat BMS-986368; CC-97489; ABX-1772	MAGL FAAH	Neurological Disease
Irafamdastat (BMS-986368) (Example 74) is a FAAH and *MAGL* inhibitor, with IC₅₀s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect .

HY-120851

O-7460	Cannabinoid Receptor DAGL	Metabolic Disease
O-7460 is a potent and selective DAGLα inhibitor, with an IC₅₀ of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels .

HY-118158

*FAAH/MAGL-IN-4*	FAAH	Neurological Disease
FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC₅₀s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .

HY-121422

JZP-361	MAGL Histamine Receptor	Inflammation/Immunology
JZP-361 is a potent, reversible and selective inhibitor of human recombinant *MAGL* (hMAGL) with an IC₅₀ of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .

HY-111512

PF-06795071	MAGL	Neurological Disease Inflammation/Immunology
PF-06795071 is a potent and selective covalent *MAGL* inhibitor with an IC₅₀ of 3 nM .

HY-136562

N-Arachidonyl maleimide	MAGL	Metabolic Disease
N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with an IC₅₀ value of 140 nM .

HY-15249R

JZL 184 (Standard)	MAGL Reference Standards	Neurological Disease
JZL 184 (Standard) is the analytical standard of JZL 184. This product is intended for research and analytical applications. JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH .

HY-117771A

DO34 analog	DAGL	Neurological Disease Metabolic Disease
DO34 analog is a structural analog of DO34 (HY-117771). DO34 is a selective DAGL inhibitor, with an IC₅₀ of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 can be used for the research of energy balance disorder and neuroinflammation .

HY-163733

AKU-005	FAAH MAGL	Neurological Disease Inflammation/Immunology
AKU-005 is a FAAH and *MAGL* dual inhibitor with IC₅₀ values of 63, 389 nM for rat and human FAAH, respectively. AKU-005 has the potential for the research of trigeminal hyperalgesia .

HY-139182

MAGL-IN-3	Endogenous Metabolite	Metabolic Disease
CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC₅₀=34.1 nM). It reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells when used at a concentration of 1 μM. CAY10762 (10 mg/kg) increases levels of 2-arachidonoyl glycerol in mouse brain.

HY-150702

MAGLi 432	MAGL	Neurological Disease Inflammation/Immunology
MAGLi 432 is a non-covalent, potent, highly selective, and reversible *MAGL* inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC₅₀ values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease .

HY-146342

*FAAH/MAGL-IN-3*	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC₅₀ values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

HY-162315

MAGL-IN-16	MAGL	Neurological Disease
MAGL-IN-16 (compound 27) is an oral active, selective and reversible *MAGL* inhibitor with the IC₅₀ value of 10.3 nM. MAGL-IN-16 can increase the level of 2-AG and shows antidepressant effect in mouse depressed model caused by chronic restraint stress .

HY-143263

*FAAH/MAGL-IN-1*	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-1 (compound SIH 3) is a potent FAAH and *MAGL* inhibitor with IC₅₀s of 31 nM and 29 nM, respectively. FAAH/MAGL-IN-1 has the potential for the research of neuropathic pain .

HY-143264

*FAAH/MAGL-IN-2*	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-2 is a potent, reversible, orally active, and cross the blood-brain barrier FAAH and *MAGL* inhibitor with IC₅₀s of 11 nM and 36 nM (K_is of 28 nM and 60 nM), respectively . FAAH/MAGL-IN-2 has the potential to research neuropathic pain without causing locomotion impairment .

HY-168032

MAGL-IN-18	MAGL	Inflammation/Immunology
MAGL-IN-18 (compound 118) is a potent Monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 0.03 nM .

HY-163202

MAGL-IN-13	MAGL Calcium Channel	Neurological Disease Cancer
MAGL-IN-13 (compound (3R, 4S) - 5v) is a selective, irreversible inhibitor for *MAGL*,with IC₅₀ values of 0.026, 0.021 and 0.24 nM for mMAGL, hMAGL and rMAGL, respectively. MAGL-IN-13 can penetrant blood brain barrier. .

HY-157040

MAGL-IN-9	MAGL	Inflammation/Immunology
MAGL-IN-9 (compound 16) is a selective and reversible *MAGL* inhibitor with IC₅₀ 2.7 nM .

HY-175270

MAGL-IN-22	MAGL Keap1-Nrf2 NF-κB	Neurological Disease Inflammation/Immunology Cancer
MAGL-IN-22 (Compound 40) is a reversible, competitive, selective and BBB-penetrable *MAGL* inhibitor with an IC₅₀ of 0.34  μM for hMAGL. MAGL-IN-22 has significant antioxidant and anti-inflammatory activity, and activates the Nrf2 pathway and significantly inhibits NFκB-mediated inflammation, without inducing cytotoxic effects. MAGL-IN-22 can be used for neurodegenerative diseases, chronic pain and cancers research .

HY-103463

SA57	FAAH MAGL	Neurological Disease
SA57 is a potent, selective FAAH inhibitor with IC₅₀s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases *MAGL* (IC₅₀s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC₅₀ of 850 nM), but not other brain serine hydrolases .

HY-146341

FAAH-IN-5	FAAH MAGL	Neurological Disease
FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

HY-116143

MAGL-IN-12	MAGL	Metabolic Disease
SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC₅₀s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis .

HY-124378

MAGL-IN-17	MAGL	Inflammation/Immunology
MAGL-IN-17 (Compound ) is an inhibitor for *MAGL* with a K_i of 0.4 μM. MAGL-IN-17 inhibits mouse MAGL and rat MAGL with IC₅₀ of 0.18 and 0.24 μM. MAGL-IN-17 exhibits anti-inflammatory activity in mouse experimental autoimmune encephalitis models .

HY-157042

MAGL-IN-11	MAGL	Inflammation/Immunology Cancer
MAGL-IN-11 (compound 29) is a selective and reversible MAGL inhibitor. MAGL-IN-11 has the potential to study inflammation, cancer and antioxidants .

HY-145945

MAGL-IN-6	MAGL	Neurological Disease
MAGL-IN-6 is a potent *MAGL* inhibitor with an IC₅₀ of 4.71 nM. MAGL-IN-6 can be used for neurological disorders research (WO2020065613A1; example 234) .

HY-168145

MAGL-IN-19	MAGL	Cancer
MAGL-IN-19 (compund 7o) is a highly potent and selective *MAGL* inhibitor .

HY-157041

MAGL-IN-10	MAGL	Cancer
MAGL-IN-10 is areversible monoacylglycerol lipase (MAGL) inhibitor with very good ADME properties and low in vivo toxicity.MAGL-IN-10 can be used for the research ofcancer, neurological disorders and inflammatory pathologies .

HY-168459

MAGL-IN-21	MAGL	Neurological Disease
MAGL-IN-21 (Compound (S)-6) is a selective inhibitor for monoacylglycerol lipase (MAGL) with an IC₅₀ of 1.59 nM .

HY-157038

MAGL-IN-8	MAGL	Inflammation/Immunology
MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC₅₀ of 2.5 ± 0.4 nM for hMAGL .

HY-169239

MAGL-IN-20	MAGL	Cancer
MAGL-IN-20 (compound ±34) is a reversible monoacylglycerol lipase (MAGL) inhibitor. MAGL-IN-20 exhibits appreciable antiproliferative activities against several cancer cells, including H460, HT29, CT-26, Huh7 and HCCLM-3. .

HY-162305

MAGL-IN-15	MAGL	Neurological Disease
MAGL-IN-15 (Compound 6) is a *MAGL* inhibitor that can be used in the research of diseases and disorders related to the regulation of endocannabinoid system signaling activities .

HY-173296

MAGL-IN-222	Lipase	Cancer
MAGL-IN-222 (Compound ZQ-7) is a covalent inhibitor targeting monoacylglycerol lipase (MAGL) with an IC₅₀ of 42.31 μM. MAGL-IN-222 can reduce the breakdown of 2-arachidonoylglycerol (2-AG) and increase the intracellular 2-AG level, thereby inhibiting the proliferation and migration of MDA-MB-231 breast cancer cells. MAGL-IN-222 can be used in the research of breast cancer and other related diseases .

HY-173369

*PROTAC MAGL* degrader-1**	PROTACs MAGL	Cancer
PROTAC MAGL degrader-1 is an orally active PROTAC agent that simultaneously targets monoacylglycerol lipase (MAGL) and E3 ubiquitin ligase MDM2. PROTAC MAGL degrader-1 degrades MAGL and inhibits the binding of MDM2 to p53. PROTAC MAGL degrader-1 can partially penetrate the blood-brain barrier (BBB). PROTAC MAGL degrader-1 induces glioblastoma stem cells (GSCs) apoptosis. (E3 ligase ligand: HY-128837; target protein ligand + linker: HY-173370; target protein inhibitor: HY-15249) .

HY-162304

MAGL-IN-14	MAGL	Neurological Disease
MAGL-IN-14 (compound 2) is a potent inhibitor of *MAGL, with IC₅₀* of 0.00289 μM and 0.002 μM in HEK293 and PC3 cells, respectively .

HY-173370

MAGL Ligand-Linker Conjugate 1	E3 Ligase Ligand-Linker Conjugates	Others
MAGL Ligand-Linker Conjugate 1 is a conjugate of the MAGL ligand and the linker. MAGL Ligand-Linker Conjugate 1 can be used for synthesis of PROTAC degrader PROTAC MAGL degrader-1 (HY-173369) .

Cat. No.	Product Name

HY-L091

Lipid Metabolism Compound Library

978 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 978 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2512

1-Monomyristin 1 Publications Verification	Infection Structural Classification Serenoa repens Classification of Application Fields Palmae Plants Disease Research Fields Steroids	Environmental Pollutants Endogenous Metabolite FAAH Autophagy Bacterial Fungal
1-Monomyristin acts as an insecticide, enzyme inhibitor, antibacterial and antifungal agent, with an IC₅₀ of 18 μM against rat FAAH and an IC₅₀ of 32 μM against rat *MAGL. 1-Monomyristin inhibits 2-oleoylglycerol hydrolysis via MAGL. 1-Monomyristin suppresses the growth of Staphylococcus aureus, Aggregatibacter actinomycetemcomitans* and Candida albicans. 1-Monomyristin is lethal to brine shrimp . 1-Monomyristin exhibits marginal cytotoxicity against prostate cancer cells. 1-Monomyristin is applicable to research related to bacterial infections, fungal infections, renal cancer, prostate adenocarcinoma and pancreatic cancer .

Species:	Human (2) Rat (1)
Tag:	His (2) Tag Free (1)
Source:	P. pastoris (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71755

	Monoglyceride lipase Protein, Rat (P.pastoris, His) Mgll; Mgl2; Monoglyceride lipase; MGL; Monoacylglycerol lipase; MAGL	Rat	P. pastoris
	Monoglyceride lipase is a key enzyme in lipid metabolism and plays a key role in converting monoacylglycerols into free fatty acids and glycerol, contributing to important cellular processes. In addition to being involved in lipid metabolism, this enzyme also hydrolyzes the endocannabinoid 2-arachidonoylglycerol, thereby affecting the complex regulation of endocannabinoid signaling, nociception, and pain perception. Monoglyceride lipase Protein, Rat (P.pastoris, His) is the recombinant rat-derived Monoglyceride lipase protein, expressed by P. pastoris , with N-His labeled tag.

HY-P701984

	MGLL Protein, Human MGLL; Monoglyceride lipase; MGL; HU-K5; Lysophospholipase homolog; Lysophospholipase-like; Monoacylglycerol lipase; MAGL	Human	E. coli
	MGLL proteins convert monoacylglycerides into free fatty acids and glycerol. MGLL Protein, Human is the recombinant human-derived MGLL protein, expressed by E. coli , with tag free.

HY-P701985

	MGLL Protein, Human (His) MGLL; Monoglyceride lipase; MGL; HU-K5; Lysophospholipase homolog; Lysophospholipase-like; Monoacylglycerol lipase; MAGL	Human	E. coli
	MGLL proteins convert monoacylglycerides into free fatty acids and glycerol. MGLL Protein, Human (His) is the recombinant human-derived MGLL protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W770198

2-Linoleoyl glycerol-d5

2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83201

	Monoacylglycerol Lipase Antibody (YA2946) HUK5; Lysophospholipase homolog; Lysophospholipase like; MAGL; MGL; MGLL; Monoacylglycerol lipase	WB	Human
	Monoacylglycerol Lipase Antibody (YA2946) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Monoacylglycerol Lipase.